Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus local ablative therapy versus docetaxel after oligoprogression on prior PD-1/PD-L1 therapy in advanced NSCLC
ChiCTR2300071193Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- May 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cadonilimab and docetaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 6-month progression-free survival rate. Started May 2023; status: recruiting.
02
Drugs
cadonilimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300071193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071193.